Short answer
Xenon Pharmaceuticals Inc. (XENE) filed an 8-K current report with the SEC on March 12, 2026 reporting Item 8.01 (Other Events), Item 1.01 (Entry into a Material Definitive Agreement). Xenon raised ~$707.7M net proceeds via public offering of 12,236,843 shares + 877,194 pre-funded warrants at $57.00/share.
Xenon Pharmaceuticals Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Xenon raised ~$707.7M net proceeds via public offering of 12,236,843 shares + 877,194 pre-funded warrants at $57.00/share
- Underwriters exercised full 30-day overallotment option (1,710,526 additional shares) same day as pricing: strong demand signal
- Underwriter discount ~5.25% ($57.00 public price vs. $54.0075 net to company)
- Pre-funded warrants priced at $56.9999 with $0.0001 exercise price: effectively equivalent to common shares, used by investors near ownership thresholds
- 4.99% beneficial ownership cap on warrant exercise (adjustable up to 19.99% with 61-day notice) limits short-term concentration risk
Item 8.01 · Other Events
- Filing references a pre-funded warrant offering: typically used when investors near ownership thresholds, suggesting large institutional buyer(s)
- Text fragment indicates details of offering terms are described elsewhere in the filing: investors should review full 8-K for pricing and size
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Xenon Pharmaceuticals Inc. 8-K filings
Get the next XENE 8-K as it lands
Follow XENE for push alerts, or ask the research agent what this filing means.